ASO Author Reflections: Rationale to Routinely Retest ER, PR and HER-2/neu Receptor Status in Residual Disease After Neoadjvuant Chemotherapy

Ann Surg Oncol. 2024 Nov;31(12):8108-8109. doi: 10.1245/s10434-024-16020-2. Epub 2024 Aug 6.

Authors

Soumy Gottipati¹, Macy Goldbach², Julia Tchou³

Affiliations

¹ Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
² Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. [email protected].

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor / metabolism
Breast Neoplasms* / drug therapy
Breast Neoplasms* / metabolism
Breast Neoplasms* / pathology
Female
Humans
Neoadjuvant Therapy
Neoplasm, Residual*
Prognosis
Receptor, ErbB-2* / metabolism
Receptors, Estrogen* / metabolism
Receptors, Progesterone* / metabolism

Substances

Receptor, ErbB-2
ERBB2 protein, human
Receptors, Estrogen
Receptors, Progesterone
Biomarkers, Tumor